Cort Johnson: ‘Peterson’s Atypical Subset Opens New View of ME/CFS in Columbia/Simmaron Publication’

Cort Johnson writes a stunning breakdown on the recent research differentiating Atypical and Classical ME/CFS by scientists at Columbia CII and Simmaron Research

The recent paper ‘Immune network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome with atypical and classical presentations’ by Dr. Mady Hornig et al is a complex paper. Cort Johnson from Health Rising has done an excellent and thorough breakdown of this recent publication in an article on the Simmaron Research website. This article should help people gain more insight and understanding of this research and includes information from Dr. Mady Hornig at the CII about the paper:

“Over the past couple of years the Simmaron Research Foundation and Center for Infection and Immunity at Columbia University and others have begun to pump out some long awaited subsets. This week, new findings were published by Columbia and Simmaron that define 2 subsets.

They’re not the usual suspects (infectious trigger vs non-infectious trigger; gradual onset vs acute onset). In fact, they involve subsets few would have predicted a couple of years ago. They suggest that we might be in for some real surprises over time.

Short Duration vs Long Duration Subset: Two years ago, the Simmaron Research Foundation collaborated with Ian Lipkin and other doctors to uncover a subset few had anticipated: short duration patients vs long duration patients.

The Atypical Patient or “Peterson Subset”:  Now comes a subset of atypical chronic fatigue syndrome (ME/CFS) patients (the “Peterson Subset”) that Dr. Peterson had long wondered about. These patients had ME/CFS but tended to follow a different course. Some had had unusual exposures (unusual infections, blood transfusions); others developed serious illnesses (cancer, autoimmune diseases, etc.) that Dr. Peterson didn’t see in the rest of the population.

Dr. Hornig talked about how the atypical subset came about. Like so many breakthroughs in medicine it took a careful and observant doctor/researcher to bring it about. This study, she said, was a testament to:

“Dr. Peterson’s clinical acumen, his long-term follow up of this patient population and his attentiveness to the full range of complex, serious medical disorders that might develop. The classical group had been followed for similar lengths of time but had not developed these more severe, serious comorbidities.”

The atypical vs classical distinction was pre-established by Dr. Peterson before the analysis. Based on his wide-ranging clinical experience, the atypical group stood out for either: 1) the presence of unusual precursors (triggers) of ME/CFS or; 2) the development of more unusual and severe comorbidities over varying (and often long-term) intervals after ME/CFS onset.”

Dr. Peterson felt the unusual outcomes weren’t just the result of chance: something different was going on – something that he felt as a doctor needed to be identified. What if, he thought, there was a way to identify these unusual patients before they started developing these significant illnesses. Then he could do more extensive cancer or immune screens and watch these patients more closely.”

Cort elucidates so much more, including more quotes from Dr. Hornig. The huge Monster study which the Microbe Discovery Project patient team are helping to fundraise for at Columbia CII is mentioned with respect to the 125 patients and 125 control group for study, where collection has already been done.

Read the full article on Simmaron’s site: ‘Peterson’s Atypical Subset Opens New View of ME/CFS in Columbia/Simmaron Publication’. Thanks to Simmaron Research and Cort Johnson!

You can see more about CII’s huge Monster study here. An NIH grant ‘partially’ funded collection, without your donations collection for this study would not have been possible. To see more about the Columbia CII current program of ME/CFS research see our MDP homepage.